Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.15
ANGO's Cash to Debt is ranked lower than
87% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. ANGO: 0.15 )
Ranked among companies with meaningful Cash to Debt only.
ANGO' s 10-Year Cash to Debt Range
Min: 0.09  Med: 4.10 Max: N/A
Current: 0.15
Equity to Asset 0.71
ANGO's Equity to Asset is ranked higher than
71% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ANGO: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
ANGO' s 10-Year Equity to Asset Range
Min: -0.01  Med: 0.79 Max: 0.93
Current: 0.71
-0.01
0.93
F-Score: 4
Z-Score: 2.03
M-Score: -2.68
WACC vs ROIC
10.59%
0.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -0.28
ANGO's Operating margin (%) is ranked lower than
65% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.48 vs. ANGO: -0.28 )
Ranked among companies with meaningful Operating margin (%) only.
ANGO' s 10-Year Operating margin (%) Range
Min: -10  Med: 7.73 Max: 13.14
Current: -0.28
-10
13.14
Net-margin (%) -0.92
ANGO's Net-margin (%) is ranked lower than
61% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. ANGO: -0.92 )
Ranked among companies with meaningful Net-margin (%) only.
ANGO' s 10-Year Net-margin (%) Range
Min: -8.13  Med: 3.27 Max: 8.75
Current: -0.92
-8.13
8.75
ROE (%) -0.60
ANGO's ROE (%) is ranked lower than
62% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. ANGO: -0.60 )
Ranked among companies with meaningful ROE (%) only.
ANGO' s 10-Year ROE (%) Range
Min: -3.97  Med: 2.73 Max: 198.83
Current: -0.6
-3.97
198.83
ROA (%) -0.41
ANGO's ROA (%) is ranked lower than
60% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. ANGO: -0.41 )
Ranked among companies with meaningful ROA (%) only.
ANGO' s 10-Year ROA (%) Range
Min: -3.51  Med: 2.59 Max: 9.77
Current: -0.41
-3.51
9.77
ROC (Joel Greenblatt) (%) -3.30
ANGO's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. ANGO: -3.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANGO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -16.13  Med: 20.84 Max: 44.35
Current: -3.3
-16.13
44.35
Revenue Growth (3Y)(%) 4.60
ANGO's Revenue Growth (3Y)(%) is ranked lower than
52% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ANGO: 4.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ANGO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 3.2  Med: 8.70 Max: 25.2
Current: 4.6
3.2
25.2
EBITDA Growth (3Y)(%) 29.70
ANGO's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. ANGO: 29.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANGO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -33.8  Med: 6.30 Max: 31.3
Current: 29.7
-33.8
31.3
EPS Growth (3Y)(%) -23.40
ANGO's EPS Growth (3Y)(%) is ranked lower than
87% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. ANGO: -23.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANGO' s 10-Year EPS Growth (3Y)(%) Range
Min: -37  Med: -0.75 Max: 100
Current: -23.4
-37
100
» ANGO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ANGO Guru Trades in Q3 2014

Paul Tudor Jones 13,824 sh (New)
Jim Simons 153,160 sh (+66.48%)
Chuck Royce 848,531 sh (+1.13%)
Mario Gabelli 86,000 sh (unchged)
Steven Cohen Sold Out
» More
Q4 2014

ANGO Guru Trades in Q4 2014

Jim Simons 371,546 sh (+142.59%)
Paul Tudor Jones 17,029 sh (+23.18%)
Mario Gabelli 83,000 sh (-3.49%)
Chuck Royce 688,331 sh (-18.88%)
» More
Q1 2015

ANGO Guru Trades in Q1 2015

Mario Gabelli 83,000 sh (unchged)
Paul Tudor Jones 13,133 sh (-22.88%)
Chuck Royce 510,303 sh (-25.86%)
Jim Simons 263,846 sh (-28.99%)
» More
Q2 2015

ANGO Guru Trades in Q2 2015

Paul Tudor Jones Sold Out
Chuck Royce 505,703 sh (-0.90%)
Mario Gabelli 80,000 sh (-3.61%)
Jim Simons 216,600 sh (-17.91%)
» More
» Details

Insider Trades

Latest Guru Trades with ANGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 22.73
ANGO's Forward P/E is ranked lower than
60% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.74 vs. ANGO: 22.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 0.98
ANGO's P/B is ranked higher than
87% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. ANGO: 0.98 )
Ranked among companies with meaningful P/B only.
ANGO' s 10-Year P/B Range
Min: 0.64  Med: 1.01 Max: 6.71
Current: 0.98
0.64
6.71
P/S 1.46
ANGO's P/S is ranked higher than
71% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. ANGO: 1.46 )
Ranked among companies with meaningful P/S only.
ANGO' s 10-Year P/S Range
Min: 1.03  Med: 1.78 Max: 5.62
Current: 1.46
1.03
5.62
PFCF 39.22
ANGO's PFCF is ranked lower than
69% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.56 vs. ANGO: 39.22 )
Ranked among companies with meaningful PFCF only.
ANGO' s 10-Year PFCF Range
Min: 8.87  Med: 38.42 Max: 285.43
Current: 39.22
8.87
285.43
POCF 19.85
ANGO's POCF is ranked lower than
53% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.43 vs. ANGO: 19.85 )
Ranked among companies with meaningful POCF only.
ANGO' s 10-Year POCF Range
Min: 8.43  Med: 20.79 Max: 241.18
Current: 19.85
8.43
241.18
Shiller P/E 133.76
ANGO's Shiller P/E is ranked lower than
93% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.14 vs. ANGO: 133.76 )
Ranked among companies with meaningful Shiller P/E only.
ANGO' s 10-Year Shiller P/E Range
Min: 33.31  Med: 52.40 Max: 151.55
Current: 133.76
33.31
151.55
Current Ratio 2.55
ANGO's Current Ratio is ranked higher than
54% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. ANGO: 2.55 )
Ranked among companies with meaningful Current Ratio only.
ANGO' s 10-Year Current Ratio Range
Min: 2.23  Med: 3.87 Max: 11.3
Current: 2.55
2.23
11.3
Quick Ratio 1.45
ANGO's Quick Ratio is ranked lower than
56% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. ANGO: 1.45 )
Ranked among companies with meaningful Quick Ratio only.
ANGO' s 10-Year Quick Ratio Range
Min: 1.36  Med: 3.14 Max: 9.83
Current: 1.45
1.36
9.83
Days Inventory 139.07
ANGO's Days Inventory is ranked lower than
55% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. ANGO: 139.07 )
Ranked among companies with meaningful Days Inventory only.
ANGO' s 10-Year Days Inventory Range
Min: 94.14  Med: 135.17 Max: 174.24
Current: 139.07
94.14
174.24
Days Sales Outstanding 59.74
ANGO's Days Sales Outstanding is ranked higher than
56% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.01 vs. ANGO: 59.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANGO' s 10-Year Days Sales Outstanding Range
Min: 45.92  Med: 59.93 Max: 207.55
Current: 59.74
45.92
207.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 290.00
ANGO's Price/Tangible Book is ranked lower than
99% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. ANGO: 290.00 )
Ranked among companies with meaningful Price/Tangible Book only.
ANGO' s 10-Year Price/Tangible Book Range
Min: 2.01  Med: 3.35 Max: 321
Current: 290
2.01
321
Price/Projected FCF 0.85
ANGO's Price/Projected FCF is ranked higher than
85% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.76 vs. ANGO: 0.85 )
Ranked among companies with meaningful Price/Projected FCF only.
ANGO' s 10-Year Price/Projected FCF Range
Min: 0.54  Med: 0.87 Max: 0.94
Current: 0.85
0.54
0.94
Price/Median PS Value 0.82
ANGO's Price/Median PS Value is ranked higher than
73% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. ANGO: 0.82 )
Ranked among companies with meaningful Price/Median PS Value only.
ANGO' s 10-Year Price/Median PS Value Range
Min: 0.62  Med: 0.99 Max: 2.86
Current: 0.82
0.62
2.86
Earnings Yield (Greenblatt) (%) -0.71
ANGO's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ANGO: -0.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANGO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -0.71  Med: 4.20 Max: 10.9
Current: -0.71
-0.71
10.9
Forward Rate of Return (Yacktman) (%) 2.32
ANGO's Forward Rate of Return (Yacktman) (%) is ranked lower than
70% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.13 vs. ANGO: 2.32 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ANGO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -16.8  Med: 1.20 Max: 6.6
Current: 2.32
-16.8
6.6

Analyst Estimate

May16 May17
Revenue(Mil) 363 375
EPS($) 0.64 0.72
EPS without NRI($) 0.64 0.72

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:UG2.Germany,
AngioDynamics Inc was incorporated in 1988 in Delaware. The Company designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company is organized in two segments: Vascular and Oncology/Surgery. The Oncology/Surgery Division includes Radiofrequency Ablation (RFA) and NanoKnife product lines. This division also includes the microwave ablation technology products obtained through the acquisition of Microsulis Medical Ltd. The Vascular division manages Fluid Management, Venous, AngioVac, Angiographic, PTA, Drainage, Thrombolytic, Micro Access Kits, Dialysis, PICC and Port product lines. The Company's product include the NAMIC Fluid Management portfolio. The NAMIC product line includes an extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers and interventional accessories. The devices are utilized together and allow clinicians to aspirate or inject contrast, saline, remove waste and monitor invasive blood pressures throughout the procedure. The venous products consist of our VenaCure EVLT laser system and Sotradecol. The AngioVac devices are for use with other manufacturer's off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of a extracorporeal bypass procedure for up to six hours. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins and surgical bypass grafts. The micro access sets provide interventional physicians a smaller introducer system for minimally-invasive procedures. Image-guided vascular access, or IGVA, involves the use of advanced imaging equipment to guide the placement of catheters that deliver primarily short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system. Radiofrequency Ablation (RFA) products use radiofrequency energy to provide a minimally invasive approach to ablating solid cancerous or benign tumors. The NanoKnife Ablation System is for the surgical ablation of soft tissue. The NanoKnife Ablation System utilizes low energy direct current electrical pulses to permanently open pores in target cell membranes. The treated tissue is then removed by the body's natural processes in a matter of weeks, mimicking natural cell death. The Acculis Microwave Tissue Ablation (MTA) System complements the full range of ablative technologies. The Company competes with Boston Scientific Corporation; Cook Medical; Cordis Corporation, a subsidiary of Johnson & Johnson, Inc.; C.R. Bard; Medical Components, Inc., or Medcomp; Arrow International, a subsidiary of TeleFlex Medical; Smiths Medical, a subsidiary of Smiths Group PLC; Vascular Solutions; Covidien subsidiaries (Kendall, VNUS, EV3) and Merit Medical
» More Articles for ANGO

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
Weekly CEO Buys Highlight: JPM, ROG, PBY, ANGO, MCHX Jul 21 2012 
Weekly CEO Buys Highlight: WINA, ANGO, FES, LTS, TBOW Apr 15 2012 
Weekly CEO Buys Highlight: PKY, TWO, UVSP, AGYS, ANGO Feb 19 2012 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 07 2011 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 07 2009 
Weekly CEO Buys Highlight: CoBiz Financial Inc, Winmark Corp, The Greenbrier Companies Inc, AngioDyn Jul 26 2009 
Weekly CEO Buys Highlight: The Greenbrier Companies, AngioDynamics, Hallmark Financial Services, Ves Apr 18 2009 

More From Other Websites
AngioDynamics to Present at the Morgan Stanley Global Healthcare Conference Sep 02 2015
AngioDynamics to Present at the Morgan Stanley Global Healthcare Conference Sep 02 2015
ANGIODYNAMICS INC Financials Aug 21 2015
Sawyer Fredericks, Local Crooner and Winner of Season Eight of "The Voice," to Perform at Third... Aug 18 2015
Research Data Published in Annals of Surgery Concludes Irreversible Electroporation Utilizing... Aug 13 2015
Research Data Published in Annals of Surgery Concludes Irreversible Electroporation Utilizing... Aug 13 2015
10-K for AngioDynamics, Inc. Aug 12 2015
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against... Aug 11 2015
ANGIODYNAMICS INC Files SEC form 10-K, Annual Report Aug 10 2015
GPM Announces Expanded Investigation of AngioDynamics, Inc. Aug 10 2015
Boston Scientific Corp. Earnings Q2*, 2015 Aug 10 2015
AngioDynamics Announces First Patient Enrollment in RAPID Outcomes Database Aug 06 2015
AngioDynamics Announces First Patient Enrollment in RAPID Outcomes Database Aug 06 2015
ANGIODYNAMICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Aug 05 2015
AngioDynamics to Present at the 35th Annual Growth Conference Aug 04 2015
AngioDynamics Begins Shipment of New Midline Catheters Aug 04 2015
AngioDynamics to Present at the Canaccord 35th Annual Growth Conference Aug 04 2015
AngioDynamics Begins Shipment of New Midline Catheters Aug 04 2015
Coverage initiated on AngioDynamics by KeyBanc Capital Mkts Jul 24 2015
AngioDynamics Q4 Earnings Meet, Sales Hit by Forex Woes - Analyst Blog Jul 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK